LAWSUITS FILED AGAINST NSP, CODX and JCOM - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / July 24, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Insperity, Inc. (NYSE:NSP)
CONTACT JAKUBOWITZ ABOUT NSP:
https://claimyourloss.com/securities/insperity-inc-loss-submission-form/?id=8160&from=1
Class Period : February 11, 2019 - February 11, 2020
Lead Plaintiff Deadline : September 21, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had failed to negotiate appropriate rates with its customers for employee benefit plans and did not adequately disclose the risk of large medical claims from these plans; (b) Insperity was experiencing an adverse trend of large medical claims; (c) as a mitigating measure, the Company would be forced to increase the cost of its employee benefit plans, causing stunted customer growth and reduced customer retention; and (d) the foregoing issues were reasonably likely to, and would, materially impact Insperity's financial results.
Co-Diagnostics, Inc. (NASDAQ:CODX)
CONTACT JAKUBOWITZ ABOUT CODX:
https://claimyourloss.com/securities/co-diagnostics-inc-loss-submission-form/?id=8160&from=1
Class Period : February 25, 2020 - May 15, 2020
Lead Plaintiff Deadline : August 17, 2020
According to the filed complaint, Co-Diagnostics and its directors and officers (including PhD-level scientists who should know better) made continual, knowing, and willful misstatements about the Company's main product, a Covid-19 diagnostic test. These misstatements had the effect of pumping up the price of Co-Diagnostics' stock while Company officers and directors exercised low-priced options and dumped their stock into the market. Co-Diagnostics' fraudulent misstatements displayed a disregard for basic scientific principles and caused investors to lose millions of dollars.
J2 Global, Inc. (NASDAQ:JCOM)
CONTACT JAKUBOWITZ ABOUT JCOM:
https://claimyourloss.com/securities/j2-global-inc-loss-submission-form/?id=8160&from=1
Class Period : October 5, 2015 - June 29, 2020
Lead Plaintiff Deadline : September 8, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) J2 Global engaged in undisclosed related party transactions; (2) J2 Global used misleading accounting to hide requisite impairments and underperformance in acquisitions; (3) several so-called independent members of the Company' board of directors and audit committee were not disinterested; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/598782/LAWSUITS-FILED-AGAINST-NSP-CODX-and-JCOM--Jakubowitz-Law-Pursues-Shareholders-Claims
